Lv1
100 积分 2024-11-03 加入
Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
1个月前
已完结
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
2个月前
已完结
Impact of secondary‐type mutations in NPM1 mutated AML
2个月前
已完结
Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
6个月前
已完结
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
6个月前
已关闭
The role of menin inhibitors in acute myeloid leukemia
6个月前
已关闭
Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia
6个月前
已完结
Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors
7个月前
已完结
Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
7个月前
已关闭
Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
7个月前
已关闭
皖公网安备34019202002308
